

Press release
25 March 2026

Resolutions of the Annual General Meeting 2026 of Curasight A/S

Copenhagen, Denmark, 25 March 2026 – today Curasight A/S ("Curasight" or the "Company" – TICKER: CURAS) held its Annual General Meeting at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE, Denmark

Today, the shareholders in Curasight passed the following resolutions at the Annual General Meeting in accordance with the agenda:

1. The Board of Directors' report on the Company's activities in the past financial year

The general meeting took note of the Board of Directors' report on the Company's activities in 2025.

2. Presentation and approval of the annual report

The general meeting adopted the Company's annual report for 2025 unanimously with all votes represented at the general meeting.

3. Resolution on appropriation of profit or covering of loss as recorded in the adopted annual report

The general meeting adopted the proposal to carry forward the result for 2025 to the next year according to the adopted annual report for 2025 with all votes represented at the general meeting.

4. Election of members to the Board of Directors

The general meeting re-elected Kirsten Aarup Drejer, Andreas Kjær, and Ulrich Krasilnikoff as members of the Board of Directors and elected Marcel Reichen and Colin Hayward as new board members replacing Lars Trolle and Charlotte Vedel with consent of all votes represented at the general meeting.

5. Election of auditor

PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab was re-elected as the Company's auditor with consent of all votes represented at the general meeting.

6. Proposed resolutions from the Board of Directors and/or the shareholders of the Company

There were no proposed resolutions from the Board of Directors and/or the shareholders of the Company.

At a board meeting held immediately after the Annual General Meeting, Kirsten Drejer was re-elected as chairman of the Board of Directors and Andreas Kjær was elected as deputy chairman of the Board of Directors.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: uk@curasight.com

www.curasight.com

Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE®) and Radioligand Therapy (uTREAT®) Theranostic Platform targeting the urokinase-type plasminogen activator receptor ("uPAR"). The technology is expected to improve diagnosis and provide more gentle and efficient treatment of multiple cancer types.